Assuntos
Articulação Acromioclavicular , Cistos , Glucocorticoides/administração & dosagem , Artropatias , Paracentese/métodos , Ultrassonografia/métodos , Articulação Acromioclavicular/diagnóstico por imagem , Articulação Acromioclavicular/patologia , Idoso de 80 Anos ou mais , Cistos/diagnóstico por imagem , Cistos/patologia , Cistos/fisiopatologia , Cistos/terapia , Humanos , Injeções Intralesionais/métodos , Artropatias/diagnóstico , Artropatias/fisiopatologia , Artropatias/terapia , Masculino , Testes Imediatos , Resultado do TratamentoAssuntos
Artralgia/diagnóstico , Fraturas do Fêmur , Fraturas Intra-Articulares/diagnóstico , Articulação do Joelho/diagnóstico por imagem , Ultrassonografia/métodos , Idoso de 80 Anos ou mais , Artralgia/etiologia , Diagnóstico Diferencial , Fraturas do Fêmur/complicações , Fraturas do Fêmur/diagnóstico , Humanos , Masculino , Testes ImediatosRESUMO
Musculoskeletal ultrasonography is gaining favor in the evaluation of enthesitis in patients with psoriasis and psoriatic arthritis (PsA). Imaging modalities have shown that the enthesis of the distal interphalangeal joint has a close relationship to the nail itself. Studies have focused on the structure and morphology of nails to determine an association between psoriasis nail changes and the presence or severity of PsA. With the use of higher frequency probes, power Doppler (PD) can determine subclinical inflammation of the area under ultrasound examination. At the 2016 meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), we proposed an ultrasonographic index for the assessment of the nail enthesis to identify the morphologic and PD findings of the nail, with the potential that both rheumatologists and dermatologists can use it to evaluate their patients.
Assuntos
Artrite Psoriásica/diagnóstico por imagem , Entesopatia/diagnóstico por imagem , Unhas/diagnóstico por imagem , Psoríase/diagnóstico por imagem , Ultrassonografia , Humanos , Índice de Gravidade de DoençaRESUMO
Systemic lupus erythematosus (SLE) is a chronic, complicated and challenging disease to diagnose and treat. The etiology of SLE is unknown, but certain risk factors have been identified that lead to immune system dysfunction with antibody formation and immune complex deposition. This immune system dysregulation causes organ injury, contributing to the variable manifestations and relapsing-remitting course of the disease. Criteria were created to aide in the diagnosis, focusing on clinical manifestations and antibody profiles specific to SLE. Treatment options are limited to a few medications to control the inflammation and decrease organ damage. Continuing investigations into the pathogenesis of SLE has led to new discoveries, making more medications available to treat this difficult disease. [Full article available at http://rimed.org/rimedicaljournal-2016-12.asp].
Assuntos
Anticorpos Monoclonais/uso terapêutico , Linfócitos B/imunologia , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/terapia , Corticosteroides/uso terapêutico , Humanos , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
Early diagnosis, use of newly developed targeted therapies, and a multispecialty approach are essential for the treatment of patients with psoriasis and psoriatic arthritis.